Shire plc SHPGY, announces that it has
reached an agreement with the Center for Drug Evaluation and Research
at the U.S. Food and Drug Administrationto conduct additional clinical
trials to confirm the clinical benefit of ProAmatine, a
medicine approved in 1996 under Subpart H
for the treatment of symptomatic orthostatic hypotension.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in